There were an estimated 68 000 new melanoma cases in the United States in 2010, and the incidence seems to be increasing.
1 At diagnosis, 82% of patients have localized disease, while in 11% disease has already spread to regional sites.
2 Any regional lymph node metastasis in melanoma decreases survival.
3 Sentinel lymph node biopsy (SLNB) for melanoma was introduced in the early 1990s to identify the presence of occult regional metastatic disease.
4 The procedure has been shown to provide important prognostic information
3,5 and obviates the need for elective regional node dissection in most patients.
6 Patients with a positive result from an SLNB may be offered more aggressive treatment, including regional node dissection, other adjuvant therapy, or enrollment in clinical trials. Quiz Ref ID Although SLNB identifies patients with microscopic nodal disease, improves regional disease control,
7 and may facilitate the escalation of treatment, it is still controversial whether there is any therapeutic benefit of the procedure, especially in terms of survival.
8-10 In fact, the only randomized clinical (RCT) to evaluate the question of a survival benefit demonstrated no difference in disease-specific survival (DSS) for those treated with an SLNB for intermediate-thickness melanoma.
11,12 A criticism of the trial has been that it was underpowered to detect a small but clinically significant survival effect.
13